Transcutaneous Carbon Dioxide Therapy Significantly Accelerates Diabetic Foot Ulcer Healing: A Multicentre Randomised Controlled Trial

<b>Background/Objectives:</b> Diabetic foot ulcers (DFUs) represent common and severe complications of diabetes mellitus (DM). The aim of our parallel-group, open-label, superiority, multicentre randomised controlled trial (RCT) was to evaluate the effectiveness of transcutaneous gaseous carbon dioxide therapy (hereinafter CO<sub>2</sub> therapy) in ulcer healing in patients with non-healing DFUs. <b>Methods:</b> A total of 115 participants (89 males and 26 females, aged 65.7 ± 10.9 years) with a non-healing DFU were randomised to the intervention (76 participants) and control (39 participants) group. Participants in the intervention group received standard of care, combined with CO<sub>2</sub> therapies administered every weekday for four consecutive weeks. Participants in the control group received only standard of care. <b>Results:</b> After 4 weeks, 49 (64.5%) ulcers in the intervention group healed, compared with three (7.7%) in the control group (primary outcome). The percentage ulcer area reduction from baseline (secondary outcome) was significantly larger (<i>p</i> ≤ 0.001) in patients from the intervention group, with the median value 100% (18.4-100%), compared to the patients from the control group, with the median value 40% (-300-100%). Patients receiving CO<sub>2</sub> therapy had 35.4-fold higher odds of ulcer healing versus controls (OR 35.4, 95% CI 6.68-187.53; <i>p</i> < 0.001), and in multivariate logistic regression, CO<sub>2</sub> therapy remained independently associated with healing, while larger baseline ulcer area was associated with lower odds of healing (OR 0.654, 95% CI 0.438-0.977; <i>p</i> = 0.038). No adverse effects were reported. <b>Conclusions:</b> CO<sub>2</sub> therapy significantly contributes to ulcer healing in patients with non-healing DFUs, with no observable adverse effects, demonstrating significant potential as an effective and safe complementary treatment of DFUs in conjunction with standard of care.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-02-13
DOI
https://doi.org/10.3390/biomedicines14020422
Primary Topic
Diabetic Foot Ulcer Assessment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Transcutaneous Carbon Dioxide Therapy Significantly Accelerates Diabetic Foot Ulcer Healing: A Multicentre Randomised Controlled Trial

Anica Badanjak, Igor Frangež, Skender Veliu, Tamara Poljičanin et al.
Biomedicines
Diabetic Foot Ulcer Assessment and Management
article

Transcutaneous Carbon Dioxide Therapy Significantly Accelerates Diabetic Foot Ulcer Healing: A Multicentre Randomised Controlled Trial

Anica Badanjak, Igor Frangež, Skender Veliu, Tamara Poljičanin, Marco Meloni, Tomislav Bulum, Helena Ban Frangež, Željko Metelko, Julija Križaj, Nikolaos Papanas, Miloš Potkonjak
article en

Abstract

<b>Background/Objectives:</b> Diabetic foot ulcers (DFUs) represent common and severe complications of diabetes mellitus (DM). The aim of our parallel-group, open-label, superiority, multicentre randomised controlled trial (RCT) was to evaluate the effectiveness of transcutaneous gaseous carbon dioxide therapy (hereinafter CO<sub>2</sub> therapy) in ulcer healing in patients with non-healing DFUs. <b>Methods:</b> A total of 115 participants (89 males and 26 females, aged 65.7 ± 10.9 years) with a non-healing DFU were randomised to the intervention (76 participants) and control (39 participants) group. Participants in the intervention group received standard of care, combined with CO<sub>2</sub> therapies administered every weekday for four consecutive weeks. Participants in the control group received only standard of care. <b>Results:</b> After 4 weeks, 49 (64.5%) ulcers in the intervention group healed, compared with three (7.7%) in the control group (primary outcome). The percentage ulcer area reduction from baseline (secondary outcome) was significantly larger (<i>p</i> ≤ 0.001) in patients from the intervention group, with the median value 100% (18.4-100%), compared to the patients from the control group, with the median value 40% (-300-100%). Patients receiving CO<sub>2</sub> therapy had 35.4-fold higher odds of ulcer healing versus controls (OR 35.4, 95% CI 6.68-187.53; <i>p</i> < 0.001), and in multivariate logistic regression, CO<sub>2</sub> therapy remained independently associated with healing, while larger baseline ulcer area was associated with lower odds of healing (OR 0.654, 95% CI 0.438-0.977; <i>p</i> = 0.038). No adverse effects were reported. <b>Conclusions:</b> CO<sub>2</sub> therapy significantly contributes to ulcer healing in patients with non-healing DFUs, with no observable adverse effects, demonstrating significant potential as an effective and safe complementary treatment of DFUs in conjunction with standard of care.

BiomedicinesVol. 14(2)
University of Rome Tor Vergata (IT), Democritus University of Thrace (GR), University of Ljubljana (SI), University of Zagreb (HR), Ljubljana University Medical Centre (SI), Perutnina Ptuj (Slovenia) (SI), Klinička bolnica Merkur (HR), Policlinico Tor Vergata (IT), Croatian Personal Data Protection Agency (HR), School of Business and Management Novo Mesto (SI), Polyclinic General Hospital (GR)
Openalex Percentile: Top 59%
Diabetic Foot Ulcer Assessment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.